$336.26
2.95%
NYSE, Apr 21, 07:44 pm CET
ISIN
US8636671013
Symbol
SYK

Stryker Stock price

$346.50
-26.99 7.23% 1M
-13.23 3.68% 6M
-13.55 3.76% YTD
+10.47 3.12% 1Y
+87.54 33.80% 3Y
+156.99 82.84% 5Y
+254.00 274.59% 10Y
NYSE, Closing price Thu, Apr 17 2025
-0.17 0.05%
ISIN
US8636671013
Symbol
SYK
Sector

Key metrics

Market capitalization $132.26b
Enterprise Value $141.88b
P/E (TTM) P/E ratio 44.63
EV/FCF (TTM) EV/FCF 40.69
EV/Sales (TTM) EV/Sales 6.28
P/S ratio (TTM) P/S ratio 5.85
P/B ratio (TTM) P/B ratio 6.40
Dividend yield 0.94%
Last dividend (FY24) $3.24
Revenue growth (TTM) Revenue growth 10.23%
Revenue (TTM) Revenue $22.60b
EBIT (operating result TTM) EBIT $5.03b
Free Cash Flow (TTM) Free Cash Flow $3.49b
Cash position $4.49b
EPS (TTM) EPS $7.76
P/E forward 30.00
P/S forward 5.39
EV/Sales forward 5.78
Short interest 1.57%
Show more

Is Stryker a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Stryker Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Stryker forecast:

23x Buy
70%
9x Hold
27%
1x Sell
3%

Analyst Opinions

33 Analysts have issued a Stryker forecast:

Buy
70%
Hold
27%
Sell
3%

Financial data from Stryker

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
22,595 22,595
10% 10%
100%
- Direct Costs 8,695 8,695
8% 8%
38%
13,900 13,900
11% 11%
62%
- Selling and Administrative Expenses 6,409 6,409
10% 10%
28%
- Research and Development Expense 1,414 1,414
9% 9%
6%
6,077 6,077
13% 13%
27%
- Depreciation and Amortization 1,050 1,050
2% 2%
5%
EBIT (Operating Income) EBIT 5,027 5,027
16% 16%
22%
Net Profit 2,993 2,993
5% 5%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Stryker directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Stryker Stock News

Positive
Kiplinger
14 days ago
Large-cap stocks are key additions to any well-rounded portfolio, but how do you find the best ones? We take a closer look here.
Neutral
GlobeNewsWire
20 days ago
VB Spine is a Strategic Partner to Stryker with Access to Mako Spine and Copilot Marc, John and Anthony Viscogliosi Lead VB Spine as Co-Chief Executive Officers NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Viscogliosi Brothers, LLC, a family-owned investment office specializing in the neuro-musculoskeletal space, today announced the successful completion of its previously announced acquisition ...
Neutral
GlobeNewsWire
20 days ago
Portage, Michigan, April 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC, as part of the newly formed company VB Spine, LLC.
More Stryker News

Company Profile

Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The Medsurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling, and reprocessed medical devices. The Neurotechnology and Spine segment pertains to spinal implants and neurovascular products. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.

Head office United States
CEO Kevin Lobo
Employees 53,000
Founded 1941
Website www.stryker.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today